Charles Schwab Investment Management Inc Viridian Therapeutics, Inc.\De Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 575,070 shares of VRDN stock, worth $9.66 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
575,070
Previous 516,213
11.4%
Holding current value
$9.66 Million
Previous $11.7 Million
6.12%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding VRDN
# of Institutions
193Shares Held
78.5MCall Options Held
575KPut Options Held
441K-
Black Rock Inc. New York, NY4.77MShares$80.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$77.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$65.2 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$63 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$57.9 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $670M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...